lifestyle.healthsourcemag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AB Science
AB Science provides an update on its clinical development program.
April 16, 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
February 24, 2026
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
February 12, 2026
AB Science reçoit un avis d’autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant
January 29, 2026
AB Science obtient un brevet japonais pour l’utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu’en 2041
January 21, 2026